Shareholders Equity: The sum of preferred and common equity items.
Urogen Pharma (URGN) had Shareholders Equity of $-8.80M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$90.40M |
|
$-126.87M |
|
$8.88M |
|
$81.52M |
|
$187.18M |
|
$-96.78M |
|
$-27.26M |
|
$-124.04M |
|
$-124.04M |
|
$-126.87M |
|
$-126.87M |
|
$-126.87M |
|
$-126.87M |
|
$-96.78M |
|
$-99.34M |
|
42.88M |
|
42.88M |
|
$-2.96 |
|
$-2.96 |
|
| Balance Sheet Financials | |
$276.13M |
|
$0.66M |
|
$9.58M |
|
$285.71M |
|
$45.95M |
|
$121.73M |
|
$248.56M |
|
$294.51M |
|
$-8.80M |
|
$-8.80M |
|
|
Shareholders Equity |
$-8.80M |
42.23M |
|
| Cash Flow Statement Financials | |
$-96.77M |
|
$-20.61M |
|
$194.62M |
|
$95.82M |
|
$173.06M |
|
$77.24M |
|
$13.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.01 |
|
-- |
|
-- |
|
1.08 |
|
-13.83 |
|
90.18% |
|
-107.06% |
|
-107.06% |
|
-109.90% |
|
-137.22% |
|
-140.35% |
|
$-97.06M |
|
-- |
|
-- |
|
-- |
|
0.32 |
|
0.96 |
|
4.45 |
|
81.97 |
|
1441.26% |
|
1441.26% |
|
-44.41% |
|
-112.35% |
|
$-0.21 |
|
$-2.26 |
|
$-2.26 |
|